Side-by-side · Research reference
CagrilintidevsKisspeptin-10
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
APhase 3HUMAN-REVIEWED35/64 cited
BPhase 2HUMAN-REVIEWED10/41 cited
Kisspeptin-10
Neuropeptide · GPR54 Agonist
Phase 1/2Clinical stage
IV / SQ · Investigational
01Mechanism of Action
Parameter
Cagrilintide
Kisspeptin-10
Primary target
Amylin receptor (AMYR) and calcitonin receptor (CTR) heterodimeric complexesBailey 2026
GPR54/Kiss1R on hypothalamic GnRH neuronsRønnekleiv 2026Collado-Sole 2026
Pathway
AMYR/CTR agonism → Central satiety signaling → Reduced food intake, delayed gastric emptying, suppressed glucagonBailey 2026
Kisspeptin → GPR54 activation → GnRH neuronal depolarization → Pulsatile GnRH release → Pituitary LH/FSH secretionLages 2026Rønnekleiv 2026
Downstream effect
Central satiety induction, prandial glucagon suppression, reduced caloric intake, weight loss, improved glycemic controlBailey 2026Yamauchi 2026
Pulsatile LH surge, FSH elevation, gonadal steroidogenesis, gametogenesis initiationLages 2026
Feedback intact?
Yes — acts via physiological amylin pathways
Yes — integrates estradiol, leptin, and IGF-1 signals to modulate HPG axisSilva 2026Rønnekleiv 2026
Origin
Second-generation non-aggregating long-acting amylin analogue designed for once-weekly dosingBailey 2026
C-terminal decapeptide of KISS1 gene product; retains full biological activity of longer kisspeptin isoforms
Antibody development
—
—
02Dosage Protocols
Parameter
Cagrilintide
Kisspeptin-10
Standard dose (combination)
Cagrilintide 2.4 mg + Semaglutide 2.4 mg (CagriSema)Yamauchi 2026
Phase 3 REDEFINE 5 trial dosing.
—
Monotherapy dosing
Dose-dependent, under investigation
Monotherapy trials reported in meta-analysis.
—
Evidence basis
Phase 3 RCT (REDEFINE 5), meta-analysis of 3 RCTs (n=3545)Yamauchi 2026Ahmed 2026
Phase 1/2 trials
Route
Subcutaneous injectionBailey 2026
IV or SQ administration
IV preferred in controlled trials for precise pulsatile delivery.
Clinical trial dose
—
Phase 1/2 investigational
Dosing protocols vary by indication (hypothalamic amenorrhea, IVF trigger).
Half-life
—
Short (minutes)
Rapid clearance; pulsatile dosing mimics physiological GnRH pulse frequency.
03Metabolic / Fat Loss Evidence
Parameter
Cagrilintide
Kisspeptin-10
Weight loss vs semaglutide
7.47% greater percentage weight lossAhmed 2026
CagriSema combination vs semaglutide monotherapy (meta-analysis).
—
Absolute weight change
Significantly greater absolute weight reductionAhmed 2026
Mean difference favoring combination therapy.
—
Glycemic benefit
Reduced fasting glucose and HbA1cAhmed 2026
Synergistic effect with semaglutide in combination.
—
Body composition
Predominant fat loss with weight reduction
—
Mitochondrial function
In vitro effects on skeletal muscle mitochondria under metabolic stress conditionsOld 2026
C2C12 myotube study; clinical relevance under investigation.
—
Key publications
REDEFINE 5 (Yamauchi 2026) · Ahmed meta-analysis 2026 · Bailey review 2026Yamauchi 2026Ahmed 2026Bailey 2026
—
04Side Effects & Safety
Parameter
Cagrilintide
Kisspeptin-10
Gastrointestinal
Nausea, diarrhea (common with incretin-based therapies)Pardali 2026
Dietary management and nutritional monitoring recommended.
—
Injection site reactions
Local reactions possible with subcutaneous administration
—
Safety profile
Generally consistent with incretin-based therapies
Phase 3 and meta-analysis safety data.
—
Tolerability
Tolerability considerations similar to GLP-1RAs
—
Muscle preservation
Lean mass considerations during weight loss
In vitro mitochondrial effects observed; clinical impact under investigation.
—
Ovarian hyperstimulation
—
Theoretical risk with supraphysiological dosing in fertility protocols
Headache
—
Mild, reported in early-phase trials
Nausea
—
Transient GI symptoms with IV bolus
Hot flashes
—
Vasomotor symptoms from LH surge
Injection site reaction
—
Erythema, mild discomfort (SQ route)
Absolute Contraindications
Cagrilintide
- ·Hypersensitivity to cagrilintide or formulation components
Kisspeptin-10
- ·Active pregnancy
- ·Hormone-sensitive malignancy (breast, ovarian, endometrial)
Relative Contraindications
Cagrilintide
- ·Severe gastrointestinal disease
- ·History of pancreatitis (incretin-based therapy consideration)
Kisspeptin-10
- ·Polycystic ovary syndrome (PCOS) without monitoring
- ·Uncontrolled thyroid dysfunction
05Administration Protocol
Parameter
Cagrilintide
Kisspeptin-10
1. Dosing frequency
Once-weekly subcutaneous injection. Long-acting formulation designed for weekly administration schedule.Bailey 2026
Reconstitute with sterile water or saline per protocol. Gently swirl — do not shake. Solution should be clear and colorless.
2. Combination form
Co-formulated with semaglutide as CagriSema for single weekly injection combining amylin and GLP-1 receptor agonism.Yamauchi 2026Bailey 2026
IV infusion for pulsatile delivery in clinical trials; SQ for outpatient protocols. IV allows precise temporal control of GnRH pulse frequency.
3. Injection site
Subcutaneous — typically abdomen, thigh, or upper arm. Rotate injection sites weekly to minimize local reactions.
Pulsatile dosing (e.g., every 60–90 min) mimics physiological GnRH pulse generator. Single-bolus protocols used for LH surge induction in fertility research.
4. Storage
Refrigerate 2–8°C. Follow product-specific storage instructions for pre-filled pens or vials. Protect from light.
Serial LH, FSH, estradiol measurements to confirm HPG axis activation. Ultrasound monitoring for ovarian response in fertility applications.
5. Dietary considerations
Nutritional monitoring recommended during treatment. Dietary management strategies important for tolerability and outcomes.Pardali 2026
Lyophilized: store at 2–8 °C, light-protected. Reconstituted: refrigerate, use within 24–48 hours per protocol.
06Stack Synergy
Cagrilintide
+ Semaglutide
StrongCagrilintide (amylin receptor agonist) and semaglutide (GLP-1 receptor agonist) act on distinct receptor systems to produce synergistic weight loss through complementary mechanisms — central satiety via amylin pathways plus incretin-mediated glucose control and appetite suppression via GLP-1. Co-formulated as CagriSema, this combination demonstrates 7.5% greater weight loss versus semaglutide monotherapy in Phase 3 trials with additional benefits on glycemic control and lipid parameters.
- CagriSema
- Cagrilintide 2.4 mg + Semaglutide 2.4 mg
- Frequency
- Once weekly subcutaneous
- Duration
- 26–52 weeks (trial data)
- Primary benefit
- Enhanced weight loss, improved glycemic control, multi-pathway metabolic modulation
Kisspeptin-10
— no documented stacks